These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30314992)

  • 21. Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans.
    Neuvonen M; Tornio A; Hirvensalo P; Backman JT; Niemi M
    Clin Pharmacol Ther; 2021 Dec; 110(6):1622-1632. PubMed ID: 34580865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.
    Mori D; Ishida H; Mizuno T; Kusumoto S; Kondo Y; Izumi S; Nakata G; Nozaki Y; Maeda K; Sasaki Y; Fujita KI; Kusuhara H
    Drug Metab Dispos; 2020 May; 48(5):387-394. PubMed ID: 32114508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
    Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
    J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.
    Mochizuki T; Zamek-Gliszczynski MJ; Yoshida K; Mao J; Taskar K; Hirabayashi H; Chu X; Lai Y; Takashima T; Rockich K; Yamaura Y; Fujiwara K; Mizuno T; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
    Clin Pharmacol Ther; 2022 Jun; 111(6):1315-1323. PubMed ID: 35292967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
    Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
    J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
    Yee SW; Giacomini MM; Shen H; Humphreys WG; Horng H; Brian W; Lai Y; Kroetz DL; Giacomini KM
    Clin Transl Sci; 2019 Jul; 12(4):388-399. PubMed ID: 30982223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability.
    Takita H; Barnett S; Zhang Y; Ménochet K; Shen H; Ogungbenro K; Galetin A
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):137-147. PubMed ID: 33289952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies.
    Yoshikado T; Aoki Y; Mochizuki T; Rodrigues AD; Chiba K; Kusuhara H; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1341-1357. PubMed ID: 35945914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
    Njumbe Ediage E; Dillen L; Vroman A; Diels L; Kunze A; Snoeys J; Verhaeghe T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():80-89. PubMed ID: 29241088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
    Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
    Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
    Mochizuki T; Aoki Y; Yoshikado T; Yoshida K; Lai Y; Hirabayashi H; Yamaura Y; Rockich K; Taskar K; Takashima T; Chu X; Zamek-Gliszczynski MJ; Mao J; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
    Clin Transl Sci; 2022 Jun; 15(6):1519-1531. PubMed ID: 35421902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.
    Shen H; Dai J; Liu T; Cheng Y; Chen W; Freeden C; Zhang Y; Humphreys WG; Marathe P; Lai Y
    J Pharmacol Exp Ther; 2016 May; 357(2):382-93. PubMed ID: 26907622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.
    Bednarczyk D; Boiselle C
    Xenobiotica; 2016; 46(5):457-66. PubMed ID: 26383540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion.
    Takehara I; Watanabe N; Mori D; Ando O; Kusuhara H
    J Pharm Sci; 2019 Aug; 108(8):2756-2764. PubMed ID: 30905707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC-0810 in humans.
    Yoshida K; Jaochico A; Mao J; Sangaraju D
    Br J Clin Pharmacol; 2023 Jun; 89(6):1903-1907. PubMed ID: 36735594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
    Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
    Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023.
    Lai Y
    Drug Metab Dispos; 2023 Aug; 51(8):950-961. PubMed ID: 37407093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
    Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
    Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions.
    Kandoussi H; Zeng J; Shah K; Paterson P; Santockyte R; Kadiyala P; Shen H; Shipkova P; Langish R; Burrrell R; Easter J; Mariannino T; Marathe P; Lai Y; Zhang Y; Pillutla R
    Bioanalysis; 2018 May; 10(9):633-644. PubMed ID: 29749254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.
    Jones NS; Yoshida K; Salphati L; Kenny JR; Durk MR; Chinn LW
    Clin Pharmacol Ther; 2020 Jan; 107(1):269-277. PubMed ID: 31376152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.